Compound ID | 179
Class: Pleuromutilin
Spectrum of activity: | Gram-positive & Gram-negative |
Details of activity: | S. aureus (MSSA, MRSA) and S. pneumoniae, along with E.coli, K.pneumoniae and E.cloacae |
Propensity to select resistant mutants: | Yes |
Institute where first reported: | Nabriva Therapeutics, Austria |
Year first mentioned: | 2010 |
Highest developmental phase: | Preclinical |
Development status: | Active |